SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001628280-22-019639
Filing Date
2022-07-28
Accepted
2022-07-28 07:20:11
Documents
14
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q/A fhtx-20220331.htm   iXBRL 10-Q/A 45639
2 EX-31.1 fhtx-20220331xex311a.htm EX-31.1 9793
3 EX-31.2 fhtx-20220331xex312a.htm EX-31.2 9772
  Complete submission text file 0001628280-22-019639.txt   256846

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fhtx-20220331.xsd EX-101.SCH 1924
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fhtx-20220331_lab.xml EX-101.LAB 33191
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fhtx-20220331_pre.xml EX-101.PRE 17453
8 EXTRACTED XBRL INSTANCE DOCUMENT fhtx-20220331_htm.xml XML 17279
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Filer) CIK: 0001822462 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-39634 | Film No.: 221112793
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences